the aid library

LIST OPTIONS

Filter

430

EPI 2: First-line anti-epileptic medication for management of acute convulsive seizures, when intravenous access is available [2015]

mhGAP; WHO (2015) C_WHO

SCOPING QUESTION: In adults with acute convulsive seizures, where intravenous access is available, which first-line anti- epileptic medication should be used to abort seizures when compared to comparator?

External Link

Full prescribing information Fexinidazole tablets, for oral use

Drugs for Neglected Diseases initiative DNDi (2021) C1

Full Perscribing information on Fexinidazole Tablet for oral use INDICATIONS AND USAGE Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati... more

Download (174)

View PDF (213)

Considerations for introducing new antiretroviral drug formulations for children

World Health Organization WHO (2020) CC

Policy brief. July 2020

Download (249)

View PDF (228)

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.

AIDSinfo; CDC Centers for Disease Control and Prevention; National Institutes of Health; et al. (2019) C2

Downloaded from https://aidsinfo.nih.gov/guidelines on 11/27/2019 Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.

Download (1202)

View PDF (4748)

Rapid advice : treatment of tuberculosis in children.

World Health Organization (2010) C_WHO

Download (498)

View PDF (654)

Rwanda: MOH GUIDELINES ON SUBMISSION OF DOCUMENTATION FOR REGISTRATION OF HUMAN PHARMACEUTICAL PRODUCTS

Ministry of Health, Rwanda (2014) C2

These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and Registration (MER) of the East African Community M... more

Download (345)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (157)

View PDF (193)

Руководство по лечению туберкулеза у детей, для национальных программ борьбы с туберкулезом

Dr. Стивена Грэхема, Dr. Малгосии Грземска, Dr. Сюзанны Хилл et al. WHO (2014) C_WHO

Как и руководство 2006 года, настоящий документ предназначен для специалистов, занимающихся разработкой государственных программ по борьбе с туберкулезом, педиатр... more

Download (182)

View PDF (217)

Toolkit for research and development of paediatric antiretroviral drugs and formulations

World Health Organization (WHO); Unitaid; Unicef; et al. World Health Organization (WHO); Unitaid; Unicef; et al. (2018) C_WHO

WHO and UNITAID in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group

Download (371)

View PDF (312)

EPI 4: Antiepileptic medications for adults and children with HIV

World Health Organization WHO (2015) C_WHO

Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?

Download (209)

View PDF (455)

EFFECTIVENESS OF SHORTENED COURSE (≤ 3 DAYS) OF ANTIBIOTICS FOR TREATMENT OF ACUTE OTITIS MEDIA IN CHILDREN

Gulani, A. & Sachdev, H.P.S World Health Organisation (WHO) (2009) C_WHO

A systematic review of randomized controlled efficacy trials | REPORT - DEPARTMENT OF CHILD AND ADOLESCENT HEALTH AND DEVELOPMENT

Download (1913)

View PDF (869)

Tanzania: GUIDELINES ON SUBMISSION OF DOCUMENTATION FOR REGISTRATION OF HUMAN PHARMACEUTICAL PRODUCTS

Tanzania Food & Drugs Authority (TFDA) (2015) C2

First Edition

Download (370)

View PDF (509)

Epilepsies: diagnosis and management
recommended

National Institute for Health and Care Excellence (NICE) (2012) C2

Clinical guideline | Published: 11 January 2012 | nice.org.uk/guidance/cg137

Download (1033)

View PDF (1763)

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, 12 September 2019

Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children AIDSinfo (2019) CC

Updated guidelines

Download (286)

View PDF (590)

New Pathways for Childhood TB Treatment

Unitaid; TB Alliance (2017) C2

Lessons from the STEP-TB Project. Accessed November 2017.

Download (799)

View PDF (1144)

National List of Essential Medicines for Adults. NEML, 6th edition, 2015 - Rwanda

Ministere de la Sante, Rwanda (2010) C_WHO

The 6th edition of the essential medicine list has been developed based on the 5th edition list of essential medicines, the National Standard Treatment Guidelines and Protocols 2013, list of laboratory commodities and List of Consumables used in public health facilities.

Download (221)

View PDF (426)

Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Centers for Disease Control and Prevention, National Center for HIVAIDS, et. al (2013) C_CDC

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of Tuberculosis Elimination.

Download (190)

View PDF (249)

EPI 3: Anti-epileptic medications for management of established status epilepticus [Updated 2015]

mhGAP; WHO (2015) C_WHO

SCOPING QUESTION: In adults with established status epilepticus (i.e., seizures persisting after the first-line treatment with benzodiazepines [or benzodiazepines-resistant status epilepticus]), which anti-epileptic medications are associated with cessation of seizures and reduced adverse effects)? ... more

Download (528)

View PDF (763)

Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Nov 2019

Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents (2017) C3

Download (232)

View PDF (232)

Annex 3. Dosages of ARV drugs

World Health Organization (2019) C_WHO

Accessed: 19.10.2019

Epilepsies: diagnosis and management recommended

Epilepsies: diagnosis and management
recommended